10-Q: PDS Biotechnology Reports First Quarter 2024 Results, Provides Clinical Pipeline Update

PDS Biotechnology reported a net loss of $10.6 million for the first quarter of 2024, while highlighting progress in its clinical trials and pipeline development.

Summary

• PDS Biotechnology reported a net loss of $10.6 million for the first quarter of 2024, compared to a net loss of $9.7 million for the same period in 2023.
• Research and development expenses increased to $6.7 million, up from $5.8 million in the first quarter of 2023, primarily due to increased clinical study costs.
• General and administrative expenses decreased slightly to $3.4 million, compared to $3.6 million in the prior year's quarter.
• The company's cash and cash equivalents totaled $66.6 million as of March 31, 2024, up from $56.6 million at the end of 2023.
• PDS Biotech is a clinical-stage immunotherapy company focused on developing targeted cancer and infectious disease immunotherapies.
• The company is advancing its Versamune and PDS01ADC product candidates through clinical trials.
• The company has no commercial products and expects to continue to incur operating losses for the foreseeable future.
• The company is funding its operations through equity and debt financings, including an at-the-market offering program and a venture loan agreement.
• The company has concluded that substantial doubt exists about its ability to continue as a going concern for a period of at least 12 months from the date of the issuance of these unaudited condensed consolidated financial statements.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is positive progress in clinical trials and pipeline development, the increasing net loss and going concern warning from auditors raise significant concerns about the company's financial stability. The company is reliant on further capital raises.

Positives

• The company's cash position improved to $66.6 million, providing resources for ongoing operations and clinical trials.
• The company successfully raised $19.5 million through its at-the-market offering program.
• The company is making progress in its clinical trials, with positive data reported for several of its product candidates.
• The company has a strong pipeline of immunotherapies targeting both cancer and infectious diseases.
• The company has secured key partnerships and licenses, including an exclusive agreement with Merck KGaA for PDS01ADC.

Negatives

• The company reported a net loss of $10.6 million for the first quarter of 2024, indicating ongoing financial challenges.
• The company has no commercial products and expects to continue to incur operating losses for the foreseeable future.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern.
• The company is dependent on additional financing to fund its operations and complete the development and commercialization of its clinical candidates.
• The company's loan agreement contains covenants, including minimum cash balance requirements, that could restrict its operations.

Risks

• The company's ability to complete clinical trials and obtain regulatory approvals is subject to significant risks and uncertainties.
• The company faces competition from other biotechnology and pharmaceutical companies.
• The company's intellectual property may not be adequately protected.
• The company's ability to raise additional capital is uncertain.
• The company's debt agreement contains covenants that could restrict its operations.
• The company's future success depends on the continued services of its employees and consultants.

Future Outlook

The company plans to continue to fund its operations and capital funding needs through existing cash and additional equity and/or debt financing. The company also plans to execute its operating plan by obtaining additional capital, principally through entering into collaborations, strategic alliances, or license agreements with third parties and/or additional public or private debt and equity financing. The company may also enter into government funding programs and consider selectively partnering for clinical development and commercialization.

Management Comments

• The company is focused on advancing its Versamune and PDS01ADC product candidates through clinical trials.
• The company believes its proprietary combination of Versamune and PDS01ADC may enhance the proliferation, potency and longevity of antigen specific multifunctional CD8 T cells in the tumor microenvironment and work synergistically to inhibit or treat cancer.
• The company is working closely with the NCI to determine the best pathway forward for the prioritized PDS01ADC studies, as well as evaluating the use of PDS01ADC in combination with other Versamune based clinical candidates.
• The company has decided to focus its near-term infectious disease activities to align with the interests of the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVICs) program.

Industry Context

The company operates in the competitive biotechnology industry, focusing on developing novel immunotherapies for cancer and infectious diseases. The company's approach of combining Versamune with PDS01ADC and its focus on T-cell activation are aligned with current trends in immunotherapy research. The company's development of a universal flu vaccine also addresses a significant unmet need in the infectious disease space.

Comparison to Industry Standards

• The company's reported median overall survival of approximately 20 months in ICI resistant HPV-positive cancers when treated with the combination of PDS0101 and PDS01ADC is significantly higher than the historical median survival of 3-4 months reported with ICIs alone and the best reported median survival to date with systemic therapy of 8.2 months in ICI resistant head and neck cancer.
• The company's 12-month overall survival rate of 87.1% in the ICI nave cohort of the VERSATILE-002 trial compares favorably to published results of 36-50% with approved ICIs used alone.
• The company's median progression-free survival of 10.4 months in the ICI nave cohort of the VERSATILE-002 trial is also higher than the published median PFS of 2-3 months for approved ICIs when used as monotherapy in patients with similar PD-L1 levels.
• The company's confirmed overall response rate of 41.2% in the ICI nave cohort of the VERSATILE-002 trial is higher than the published results of approximately 19% for approved ICIs, used as monotherapy for recurrent or metastatic head and neck cancer.
• The company's 24-month overall survival rate of 74% in the ICI nave cohort of the VERSATILE-002 trial is significantly higher than the published 24-month survival rate of less than 30% for approved ICI.
• The company's 12-month OS rate of 56% in the ICI refractory cohort of the VERSATILE-002 trial is significantly higher than the published median 12-month OS rate of 17% with no salvage chemotherapy following tumor progression on ICI (ICI Resistant).
• The company's 75% survival of ICI nave patients at 36 months in the NCI-led trial is significantly higher than the published median overall survival (OS) in similar patients of 7-11 months.
• The company's median OS of 21 months in 29 checkpoint inhibitor resistant patients who received the triple combination in the NCI-led trial is significantly higher than the reported historical median OS in patients with ICI resistant disease of 3-4 months seen with checkpoint inhibitors and best reported median survival to date with systemic therapy of 8.2 months in ICI resistant head and neck cancer.

Management Changes

Stakeholder Impact

• Shareholders face the risk of further dilution due to potential equity financings.
• Employees may be impacted by the company's financial instability and potential restructuring.
• Customers and partners may be affected by the company's ability to continue its operations and development programs.
• Creditors face the risk of non-payment if the company is unable to secure sufficient financing.

Next Steps

• The company plans to continue advancing its clinical trials for Versamune and PDS01ADC product candidates.
• The company plans to submit its IND package for PDS0103 by the end of 2024.
• The company plans to continue working with the NCI to determine the best pathway forward for the prioritized PDS01ADC studies.
• The company plans to evaluate the use of PDS01ADC in combination with other Versamune based clinical candidates.
• The company plans to continue development of a universal seasonal flu vaccine and the potential development of a universal pandemic influenza vaccine based on similar computationally designed antigens as have shown promise with Infectimune.

Key Dates

Keywords

immunotherapy, clinical trials, cancer, infectious diseases, Versamune, PDS01ADC, Infectimune, T cells, biotechnology, oncology